Listen to this article

GenScript Biotech Corp. is again expanding its global presence with a new operations site and logistics center in Sydney, Australia. 

The Piscataway-headquartered life sciences company announced the move Nov. 11. GenScript said the expansion supports “the rapid growth of the biotechnology sector in Australia” as well as “underscores the company’s determination to strengthen [its] presence in the Asia-Pacific region and globally.” 

According to GenScript, the new site will also ensure faster and more efficient delivery of research reagents and products. 

“Australian researchers and biotech companies will no longer need to navigate the complexities of permit applications, customs clearance, and tax payments, streamlining the procurement process, and allowing them to focus on advancing their groundbreaking research and innovation,” the company added in a statement. 

The Sydney site introduces next-day shipping for high-demand products, such as off-the-shelf mRNA, growth factors, Cas proteins and more, GenScript added. 

Expanding operations

Sherry Shao, GenScript’s rotating CEO, said the new site expands operations. According to her, it also builds long-term relationships with the region’s biotech ecosystem. 

“By removing import barriers and offering next-day delivery on key products, we are helping our customers focus entirely on advancing their research, without the logistical challenges that previously existed,” Shao added. 

The new location follows other domestic and international expansions for the company, including: 

• October 2024: Subsidiary Legend Biotech Corp.’s new, 31,000-square-foot state-of-the-art R&D facility in Philadelphia to advance its portfolio of next-generation cell therapies; 
• May 2023: A new 91,310-square-foot life sciences facility in the city of Zhenjiang in China’s Jiangsu Province; 
• February 2023: The expansion of its Singapore facility to approximately 38,000 square feet, allowing for a premium gene synthesis service. 

Founded in 2002, GenScript Biotech serves more than 200,000 customers across 100 countries and boasts a team of more than 5,000 employees. It operates across four major business units are:

• Life-science services and products,
• Biologics contract development and manufacturing organization (CDMO)
• Industrial synthetic products
• Cell Therapy Business Unit